GCIM
ABBV icon

Gunn & Company Investment Management’s AbbVie ABBV Stock Holding History

Gunn & Company Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,457
Closed -$764K – 62
2024
Q2 		$764K Buy
+4,457
New +$738K 0.05% 76
2024
Q1 		– Sell
-3,477
Closed -$539K – 60
2023
Q4 		$539K Buy
+3,477
New +$507K 0.04% 73

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Gunn & Company Investment Management's ABBV Position: Q3 2024 in Review

Gunn & Company Investment Management sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 4,457 shares — an estimated $764K sold.

Gunn & Company Investment Management first reported a position in ABBV in Q4 2023 and held it in 2 quarters. The position peaked at $764K in Q2 2024. 3,500 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • Gunn & Company Investment Management reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
  • Gunn & Company Investment Management sold 4,457 AbbVie shares in Q3 2024, an estimated $764K.
  • Gunn & Company Investment Management first reported a position in AbbVie in Q4 2023 and held it in 2 quarters.
  • Gunn & Company Investment Management's AbbVie position peaked at $764K in Q2 2024.
  • 3,500 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Gunn & Company Investment Management's 13F filing for Q3 2024, filed 22 Oct 2024.